AMGEN INC (AMGN) is held by 6 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 2 funds adding and 6 funds trimming or exiting versus the previous quarter. 1 member of Congress reported 2 purchases vs 6 sales. Latest close $443.89 as of Nov 18, 2026.
Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: none in the last 90 days · Congress to Nov 16, 2026.
Matrix Asset Advisors · Torray Investment Partners LLC · Sarasin & Partners — 6 tracked funds hold AMGN. See all holders.
1 member of Congress reported buying (2 purchases vs 6 sales). Latest buy: Sep 22, 2026. Politician trading
ISHARES RUSSELL 2000 ETF (IWM) · TARGET CORP (TGT) · GILEAD SCIENCES, INC. (GILD) · ISHARES RUSSELL 1000 GROWTH (IWF) · L3HARRIS TECHNOLOGIES, INC. /DE/ (LHX) — stocks the same funds also hold. See all related stocks.
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| Matrix Asset Advisors | 3.03% | 102,817 | ADDED (+3.0%) Q3 filed Oct 13 |
| Torray Investment Partners LLC | 2.92% | 59,771 | ADDED (+10.7%) Q3 filed Oct 30 |
| Sarasin & Partners | 1.46% | 343,948 | TRIMMED (-48.4%) Q3 filed Oct 13 |
| Mairs & Power Funds | 0.02% | 4,924 | TRIMMED (-0.8%) Q3 filed Nov 16 |
| Atalanta Sosnoff Capital | 0.01% | 863 | TRIMMED (-11.8%) Q3 filed Nov 10 |
| Dodge & Cox Funds | <0.01% | 12,817 | TRIMMED (-4.1%) Q3 filed Nov 13 |
| Check Capital Management | — | — | EXITED |
| OrbiMed Advisors | — | — | EXITED |
Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.
Price change since quarter-end: +26.7% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.
Tracked funds holding this stock, by quarter (2016Q3–2016Q3, 1 quarters). Source: quarterly BEST lists from 13F filings — tracked funds only, not all filers. A stock appears here only if it ever made a quarterly BEST list.
| Institutions holding | 3,157 of 8,857 filers |
| Long-only filers among them | 3,145 |
| Change vs 2026 Q1 | +50 net · 2,012 entered · 1,962 exited |
| Shares reported, all filers | 442,059,192 |
| Reported value, all filers | $159.3B |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) (SIC 2836) |
| Revenue · FY2025 | $36.8B |
| Net income · FY2025 | $7.7B |
| Total assets · FY2025 | $90.6B |
| Shares outstanding | 540,632,005 |
| Market cap (at latest close) | $240.0B |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Jul 30, 2026.
| Shares short · Oct 15, 2026 | 13,378,638 |
| Share of shares outstanding | 2.47% |
| Days to cover | 4.97 |
Shares short at recent settlements — Jul 31, 2026: 13.3M · Aug 14, 2026: 12.0M · Aug 31, 2026: 13.0M · Sep 15, 2026: 14.1M · Sep 30, 2026: 14.0M · Oct 15, 2026: 13.4M.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jul 30, 2026.
| Shares failed to deliver · Oct 14, 2026 | 0 |
| Share of shares outstanding | 0.00% |
| Fails as a share of short interest · Oct 15, 2026 | 0.0% |
Fails to deliver at recent settlements — Jul 31, 2026: 2K · Aug 14, 2026: 144 · Aug 31, 2026: 4K · Sep 15, 2026: 0 · Sep 30, 2026: 9K · Oct 14, 2026: 0.
Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Jul 30, 2026.
Data unavailable — no Form 4 transactions for this ticker were parsed in the last 90 days.
| Filed | Seller | Role | Shares to sell | Market value | Approx. sale date | Source |
|---|---|---|---|---|---|---|
| Aug 13, 2026 | Khosla Rachna | Officer | 1,252 | $516.8K | Aug 13, 2026 | SEC filing |
| Aug 11, 2026 | Khosla Rachna | Officer | 2,000 | $828.4K | Aug 11, 2026 | SEC filing |
| Aug 6, 2026 | Grygiel Nancy A. | Officer | 2,970 | $1.2M | Aug 6, 2026 | SEC filing |
| Aug 6, 2026 | Grygiel Nancy A. | Officer | 2,670 | $1.2M | Aug 6, 2026 | SEC filing |
| Aug 6, 2026 | Derek Miller | Officer | 3,890 | $1.6M | Aug 6, 2026 | SEC filing |
| May 4, 2026 | Grygiel Nancy A. | Officer | 1,237 | $400.4K | May 4, 2026 | SEC filing |
| Feb 27, 2026 | Santos Esteban | Associate | 54,792 | $20.8M | Feb 26, 2026 | SEC filing |
| Feb 19, 2026 | Busch Matthew C. | ASSOCIATED TO AFFILIATE | 1,000 | $375.0K | Feb 19, 2026 | SEC filing |
| Nov 20, 2025 | Grygiel Nancy A. | Officer | 3,139 | $1.1M | Nov 20, 2025 | SEC filing |
| Nov 12, 2025 | Khosla Rachna | Officer | 890 | $300.3K | Nov 12, 2025 | SEC filing |
A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.
| Filed | Filer | Form | Shares | % owned | Event date | Source |
|---|---|---|---|---|---|---|
| May 14, 2026 | Capital World Investors | SC 13G | 29,596,119 | 5.5% | Mar 31, 2026 | SEC filing |
| Apr 29, 2026 | Vanguard Capital Management | SC 13G | 40,510,484 | 7.5% | Mar 31, 2026 | SEC filing |
| Mar 26, 2026 | The Vanguard Group | SC 13G/A | 0 | 0.0% | Mar 13, 2026 | SEC filing |
| Sep 8, 2025 | The Vanguard Group | SC 13G/A | 53,860,795 | 10.0% | Aug 29, 2025 | SEC filing |
| Apr 17, 2025 | BlackRock, Inc. | SC 13G/A | 40,830,830 | 7.6% | Mar 31, 2025 | SEC filing |
One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.
1 member of Congress reported buying (2 purchases vs 6 sales). Bought by Republicans. Latest buy: Sep 22, 2026.
Source: U.S. House Clerk and U.S. Senate eFD STOCK Act periodic transaction reports, as of Nov 16, 2026. Reported amounts are ranges, and reports can arrive up to 45 days after the trade.
Recent activity by member
| Member | Chamber | Party | Buys | Sells | Latest | Amount range |
|---|---|---|---|---|---|---|
| Taylor, David J. | House | R | 2 | 4 | Nov 3, 2026 | $1,001 - $15,000 |
| Whitehouse, Sheldon | Senate | D | 0 | 1 | Aug 12, 2026 | $1,001 - 15,000 |
| Salazar, Maria Elvira | House | R | 0 | 1 | Apr 17, 2026 | $15,001 - $50,000 |
Member-level activity in the current window, most recent first (House data to Nov 16, 2026, Senate to Oct 1, 2026). House reports arrive as PDFs without transaction-level rows in the current corpus, so this table shows per-member totals, not individual trades; the member page lists the underlying filings. Senate rows link the same way — the member page carries the eFD filing links.
Industry: Biological Products, (No Diagnostic Substances) (SIC 2836). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.
None of the members who traded this stock in the current window sit on these committees.
Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.
Lobbying: 1,762 Lobbying Disclosure Act filings named this company as client, 1999–2026; most common issues: Medicare/Medicaid (988), Health Issues (880), Taxation/Internal Revenue Code (427).
Federal contracts: $507.5M in obligated amounts, fiscal years 2021–2026.
| Fiscal year | Obligated amount |
|---|---|
| FY2021 | $137.1K |
| FY2022 | $292.7M |
| FY2023 | $212.3M |
| FY2024 | $128.7K |
| FY2025 | $2.3M |
| FY2026 | $0 |
Largest awards collected
| Award ID | Agency | Amount | Start |
|---|---|---|---|
| 75A50118F33004 | Department of Health and Human Services | $154.4M | Sep 13, 2018 |
| 75A50119C00061 | Department of Health and Human Services | $26.4M | Sep 26, 2019 |
| 75A50123C00040 | Department of Health and Human Services | $7.3M | Aug 28, 2023 |
| 36C24521F0279 | Department of Veterans Affairs | $74.7K | Apr 9, 2021 |
| 15B61421FWB110130 | Department of Justice | $10.8K | Mar 31, 2021 |
Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.
Politicians
· Bought by Members — Last 6 months: bought by a member of the U.S. Congress
Financial Screens
· Buffett — Companies with high ROE sustained for more than a decade
· Growth — Revenue up every year for 5 straight years
· Dividend Growth — Dividends raised for more than 10 years
· Earnings Quality (Cash Conversion) — Profits that actually come back as cash
· Earnings Stability — Small earnings swings and almost no loss years
Chart Signals
· Monthly Uptrend — Price above its 12-month moving average
· Top Relative Strength — Top 20% of the universe by 6-month return
Key figures
· Buffett — Latest ROE: 89.1% · Years ROE ≥15% (of 10): 9 · 10-yr avg ROE: 79.2% · Latest net income: $7.7B
· Growth — Latest revenue: $36.8B · 5-yr revenue CAGR: 7.6% · Straight growth years: 6
· Dividend Growth — Dividend per share: 9.66 · Dividend yield: 2.1% · Straight dividend years: 10 · 10-yr dividend growth: 132.8%
· Earnings Quality (Cash Conversion) — Cash conversion (3-yr avg): 1.79 · Operating cash flow: $10.0B · Net income: $7.7B
· Earnings Stability — Earnings variation (CV): 0.29 · Loss years (of 10): 0 · Latest net income: $7.7B
· Bought by Members — Members buying: 1 · Buy txns: 2 · Sell txns: 6 · Latest buy: Sep 22, 2026
Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.
· Super-investor 13F BEST — appeared in 1 of the last 40 quarterly lists; latest 2016 Q3, ranked #50 of 50.
· Politician BEST — appeared in 10 of the last 20 quarterly lists; latest 2026 Q1, ranked #32 of 50.
| 13F signal (2021 Q3 – 2026 Q1) | Events | Win rate | Avg return | SPY | Excess |
|---|---|---|---|---|---|
| Heavy accumulation — 3+ tracked funds increased together | 10 | 70.0% | +4.7% | +3.5% | +1.2% |
| Share count tripled (3x) | 1 | 0.0% | -6.1% | -2.5% | -3.6% |
| Heavy exit — 3+ tracked funds sold out together | 1 | 100.0% | +9.6% | +5.6% | +4.0% |
Measured from SEC 13F filings: entry at the close on the first trading day after each quarter’s filing deadline, exit one quarter later on the same rule, dividend-adjusted closes. Past records do not guarantee future results — see Track Record and Methodology.
Also held by the tracked funds that hold AMGN — ranked by lift, the co-holding pattern described in Methodology: ISHARES RUSSELL 2000 ETF (IWM) · TARGET CORP (TGT) · GILEAD SCIENCES, INC. (GILD) · ISHARES RUSSELL 1000 GROWTH (IWF) · L3HARRIS TECHNOLOGIES, INC. /DE/ (LHX) · 3M CO (MMM) · VANGUARD FTSE EMERGING MARKE (VWO) · INTERNATIONAL BUSINESS MACHINES CORP (IBM).
Filings audit: every filing lens on AMGEN INC (AMGN), scored — GetCoattail Research.
| Filed | Items | Source |
|---|---|---|
| Nov 3, 2026 | 2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits | SEC filing |
| Oct 27, 2026 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers | SEC filing |
| Aug 4, 2026 | 2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits | SEC filing |
Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.
ISHARES RUSSELL 2000 ETF (IWM) · Filings audit: every filing lens on AMGEN INC (AMGN), scored · Practice timing on AMGN
One email a week: the week’s new filings and research. Subscribe free
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.